Trial Profile
A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Crizotinib (Pf-02341066) In Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Crizotinib (Primary)
- Indications Adenocarcinoma; Adrenal cancer; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 15 Nov 2019 Status changed from active, no longer recruiting to completed.
- 20 Jun 2019 Planned End Date changed from 31 Jul 2018 to 30 Aug 2019.
- 06 Jun 2017 Results (n=37; as of Aug 5, 2016), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology